Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 7 | 2026 | 713 | 1.930 |
Why?
|
| Adenocarcinoma | 9 | 2024 | 972 | 1.730 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2026 | 165 | 1.510 |
Why?
|
| Colorectal Neoplasms | 5 | 2025 | 623 | 0.860 |
Why?
|
| Circulating Tumor DNA | 2 | 2022 | 35 | 0.830 |
Why?
|
| Oncolytic Viruses | 1 | 2024 | 75 | 0.800 |
Why?
|
| Antigens, Neoplasm | 1 | 2026 | 399 | 0.780 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 222 | 0.740 |
Why?
|
| Ikaros Transcription Factor | 2 | 2022 | 29 | 0.710 |
Why?
|
| Transaminases | 2 | 2022 | 36 | 0.700 |
Why?
|
| Anemia | 1 | 2024 | 341 | 0.650 |
Why?
|
| Needs Assessment | 2 | 2025 | 170 | 0.600 |
Why?
|
| Colonic Neoplasms | 2 | 2019 | 257 | 0.590 |
Why?
|
| Safety-net Providers | 1 | 2020 | 84 | 0.590 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2026 | 873 | 0.590 |
Why?
|
| Oncologists | 1 | 2019 | 31 | 0.580 |
Why?
|
| Documentation | 1 | 2019 | 118 | 0.560 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2018 | 61 | 0.560 |
Why?
|
| Exophthalmos | 1 | 2018 | 30 | 0.550 |
Why?
|
| Minority Groups | 1 | 2020 | 256 | 0.540 |
Why?
|
| Bacteremia | 2 | 2021 | 420 | 0.540 |
Why?
|
| Orbital Neoplasms | 1 | 2018 | 45 | 0.530 |
Why?
|
| Orbit | 1 | 2018 | 79 | 0.520 |
Why?
|
| Neuroendocrine Tumors | 1 | 2018 | 58 | 0.520 |
Why?
|
| T-Lymphocytes | 1 | 2026 | 1712 | 0.520 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 124 | 0.520 |
Why?
|
| Cholangiocarcinoma | 1 | 2018 | 124 | 0.520 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 492 | 0.510 |
Why?
|
| Neoadjuvant Therapy | 6 | 2023 | 385 | 0.510 |
Why?
|
| Rectal Neoplasms | 3 | 2023 | 76 | 0.500 |
Why?
|
| Oncolytic Virotherapy | 1 | 2017 | 89 | 0.480 |
Why?
|
| Stomach Neoplasms | 3 | 2019 | 565 | 0.480 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2014 | 4 | 0.450 |
Why?
|
| Cholestasis, Extrahepatic | 1 | 2014 | 7 | 0.440 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2014 | 23 | 0.440 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 542 | 0.430 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 1310 | 0.400 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 756 | 0.390 |
Why?
|
| Physicians | 1 | 2019 | 623 | 0.380 |
Why?
|
| Electronic Health Records | 1 | 2019 | 781 | 0.370 |
Why?
|
| Aged | 14 | 2026 | 20512 | 0.370 |
Why?
|
| Neoplasms | 2 | 2025 | 2852 | 0.330 |
Why?
|
| Middle Aged | 15 | 2026 | 27886 | 0.330 |
Why?
|
| Adult | 17 | 2026 | 30603 | 0.320 |
Why?
|
| Neoplasm Staging | 7 | 2023 | 1291 | 0.310 |
Why?
|
| Humans | 30 | 2026 | 127501 | 0.280 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 1350 | 0.280 |
Why?
|
| Aspergillosis | 2 | 2004 | 46 | 0.270 |
Why?
|
| Lymphatic Metastasis | 2 | 2019 | 425 | 0.260 |
Why?
|
| Female | 17 | 2026 | 68765 | 0.260 |
Why?
|
| Male | 17 | 2026 | 62895 | 0.260 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 627 | 0.250 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2018 | 63 | 0.250 |
Why?
|
| Paclitaxel | 2 | 2024 | 129 | 0.250 |
Why?
|
| Anal Canal | 2 | 2023 | 79 | 0.240 |
Why?
|
| Aspergillus | 1 | 2004 | 26 | 0.220 |
Why?
|
| Mannans | 1 | 2004 | 14 | 0.220 |
Why?
|
| Lung Diseases, Fungal | 1 | 2004 | 37 | 0.220 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2004 | 150 | 0.220 |
Why?
|
| Albumins | 1 | 2024 | 89 | 0.210 |
Why?
|
| Health Services Needs and Demand | 1 | 2025 | 169 | 0.210 |
Why?
|
| Bayes Theorem | 1 | 2024 | 288 | 0.190 |
Why?
|
| Communicable Diseases | 1 | 2004 | 153 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 1055 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 1485 | 0.170 |
Why?
|
| Blood Culture | 1 | 2021 | 36 | 0.170 |
Why?
|
| DNA Methylation | 2 | 2025 | 1032 | 0.170 |
Why?
|
| Gastrointestinal Diseases | 1 | 2004 | 337 | 0.170 |
Why?
|
| Aged, 80 and over | 6 | 2025 | 6716 | 0.170 |
Why?
|
| Cancer Vaccines | 1 | 2022 | 188 | 0.160 |
Why?
|
| Stress, Psychological | 1 | 2025 | 553 | 0.160 |
Why?
|
| Lymph Nodes | 2 | 2019 | 374 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 1239 | 0.160 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 200 | 0.160 |
Why?
|
| Epigenesis, Genetic | 1 | 2025 | 712 | 0.160 |
Why?
|
| Fraud | 1 | 2019 | 15 | 0.150 |
Why?
|
| Acute Disease | 2 | 2018 | 1142 | 0.150 |
Why?
|
| Genetic Therapy | 1 | 2024 | 683 | 0.150 |
Why?
|
| Medically Uninsured | 1 | 2020 | 76 | 0.150 |
Why?
|
| Carcinoma, Small Cell | 1 | 2019 | 39 | 0.150 |
Why?
|
| DNA Mismatch Repair | 1 | 2018 | 45 | 0.150 |
Why?
|
| Leucovorin | 3 | 2023 | 52 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2048 | 0.140 |
Why?
|
| Fluorouracil | 3 | 2023 | 132 | 0.140 |
Why?
|
| Treatment Outcome | 6 | 2026 | 12583 | 0.140 |
Why?
|
| Physical Examination | 1 | 2019 | 168 | 0.140 |
Why?
|
| Gastrectomy | 1 | 2019 | 98 | 0.140 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 318 | 0.140 |
Why?
|
| Myxoma virus | 1 | 2017 | 1 | 0.130 |
Why?
|
| Parvovirus | 1 | 2017 | 7 | 0.130 |
Why?
|
| Orthoreovirus, Mammalian | 1 | 2017 | 7 | 0.130 |
Why?
|
| Measles virus | 1 | 2017 | 16 | 0.130 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2018 | 74 | 0.130 |
Why?
|
| Vaccinia virus | 1 | 2017 | 50 | 0.130 |
Why?
|
| Simplexvirus | 1 | 2017 | 100 | 0.130 |
Why?
|
| Retrospective Studies | 5 | 2021 | 17080 | 0.120 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 882 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2022 | 742 | 0.120 |
Why?
|
| Ethics, Medical | 1 | 2019 | 399 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2023 | 384 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 1206 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 482 | 0.110 |
Why?
|
| Histocytochemistry | 1 | 2014 | 85 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2014 | 63 | 0.110 |
Why?
|
| Adenoviridae | 1 | 2017 | 573 | 0.110 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 148 | 0.100 |
Why?
|
| Microscopy | 1 | 2014 | 123 | 0.100 |
Why?
|
| Esophagoscopy | 1 | 2014 | 164 | 0.100 |
Why?
|
| Organ Sparing Treatments | 2 | 2023 | 42 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 1110 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 535 | 0.090 |
Why?
|
| Deoxycytidine | 2 | 2023 | 82 | 0.090 |
Why?
|
| Health Status Disparities | 1 | 2015 | 269 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1601 | 0.090 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 1235 | 0.080 |
Why?
|
| Chemoradiotherapy | 2 | 2023 | 118 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 2519 | 0.080 |
Why?
|
| Mass Screening | 1 | 2015 | 805 | 0.070 |
Why?
|
| Preoperative Care | 2 | 2023 | 355 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2023 | 900 | 0.070 |
Why?
|
| Genetic Testing | 1 | 2015 | 1057 | 0.070 |
Why?
|
| Algorithms | 1 | 2015 | 1638 | 0.070 |
Why?
|
| Biomarkers, Tumor | 2 | 2025 | 1562 | 0.060 |
Why?
|
| Foodborne Diseases | 1 | 2004 | 12 | 0.060 |
Why?
|
| Meningococcal Vaccines | 1 | 2005 | 30 | 0.060 |
Why?
|
| Protozoan Infections | 1 | 2004 | 15 | 0.060 |
Why?
|
| Galactose | 1 | 2004 | 53 | 0.060 |
Why?
|
| Splenectomy | 1 | 2005 | 62 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 237 | 0.050 |
Why?
|
| Young Adult | 4 | 2019 | 9702 | 0.050 |
Why?
|
| Itraconazole | 1 | 2003 | 23 | 0.050 |
Why?
|
| Fluconazole | 1 | 2003 | 48 | 0.050 |
Why?
|
| Pneumococcal Vaccines | 1 | 2005 | 174 | 0.050 |
Why?
|
| Organoplatinum Compounds | 1 | 2023 | 33 | 0.050 |
Why?
|
| Age of Onset | 1 | 2025 | 611 | 0.050 |
Why?
|
| Preoperative Period | 1 | 2023 | 88 | 0.050 |
Why?
|
| Survival Rate | 2 | 2019 | 2110 | 0.050 |
Why?
|
| Pneumococcal Infections | 1 | 2005 | 278 | 0.050 |
Why?
|
| Antibodies, Bacterial | 1 | 2005 | 421 | 0.050 |
Why?
|
| Social Support | 1 | 2025 | 369 | 0.050 |
Why?
|
| Streptococcus pneumoniae | 1 | 2005 | 380 | 0.050 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2022 | 24 | 0.050 |
Why?
|
| Virus Diseases | 1 | 2004 | 271 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2003 | 231 | 0.050 |
Why?
|
| Bacterial Infections | 1 | 2004 | 322 | 0.040 |
Why?
|
| Psychometrics | 1 | 2025 | 655 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 204 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2003 | 296 | 0.040 |
Why?
|
| Incidence | 3 | 2017 | 3261 | 0.040 |
Why?
|
| Standard of Care | 1 | 2022 | 133 | 0.040 |
Why?
|
| Registries | 2 | 2019 | 1540 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 2080 | 0.040 |
Why?
|
| Caregivers | 1 | 2025 | 562 | 0.040 |
Why?
|
| Prognosis | 2 | 2019 | 4803 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 69 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 2019 | 87 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 303 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2019 | 83 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2019 | 120 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 154 | 0.040 |
Why?
|
| Recurrence | 1 | 2022 | 1422 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2022 | 1500 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 261 | 0.030 |
Why?
|
| United States | 3 | 2019 | 11425 | 0.030 |
Why?
|
| Rectum | 1 | 2018 | 100 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2019 | 424 | 0.030 |
Why?
|
| General Surgery | 1 | 2019 | 219 | 0.030 |
Why?
|
| Stomach | 1 | 2019 | 267 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2004 | 1167 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 3710 | 0.030 |
Why?
|
| Animals | 1 | 2017 | 33212 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2019 | 1218 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2025 | 4987 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 1370 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 3937 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 1198 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1563 | 0.030 |
Why?
|
| Biomarkers | 1 | 2023 | 3252 | 0.030 |
Why?
|
| Quality of Life | 1 | 2023 | 2032 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 2240 | 0.020 |
Why?
|
| Adolescent | 2 | 2019 | 20156 | 0.020 |
Why?
|
| Texas | 1 | 2017 | 3564 | 0.020 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2005 | 25 | 0.010 |
Why?
|
| Drug Resistance, Fungal | 1 | 2003 | 28 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 793 | 0.010 |
Why?
|
| Risk Factors | 1 | 2015 | 10636 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2003 | 632 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2005 | 3076 | 0.010 |
Why?
|